Elevated Levels of Procoagulant Microparticles in a Patient with Myocardial Infarction, Antiphospholipid Antibodies and Multifocal Cardiac Thrombosis

Overview

Journal Thromb J

Publisher Biomed Central

Date 2005 Oct 13

PMID 16219103

Citations 10

Authors

O Morel

L Jesel

J M Freyssinet

F Toti

Affiliations

Soon will be listed here.

Abstract

Circulating procoagulant microparticles (MP) are pathogenic markers of enhanced coagulability associated to a variety of disorders and released from stimulated vascular cells. When derived from endothelial cells, MP were found characteristic of thrombotic propensity in primary antiphospholipid syndrome (APS). The prothrombotic status of a patient with antiphospholipid antibodies (APL), a past history of mesenteric vein thrombosis and presenting myocardial infarction and extensive intracardiac thrombosis was examined by measurement of circulating procoagulant MP. MP of platelet and endothelial origins were highly elevated with respect to values detectable in patients with myocardial infarction and no history of APS (6- and 3-fold elevation, respectively) or in healthy volunteers (13- and 25-fold elevation, respectively). In this particular patient, with moderate APL titer, a drastic release of procoagulant MP could have contributed to thrombus growth and the development of extensive intracardiac thrombosis.

Citing Articles

S100A8/A9 drives the formation of procoagulant platelets through GPIbα.

Colicchia M, Schrottmaier W, Perrella G, Reyat J, Begum J, Slater A Blood. 2022; 140(24):2626-2643.

PMID: 36026606 PMC: 10653093. DOI: 10.1182/blood.2021014966.

Surprisingly low incidence of left ventricular thrombosis in anterior ST-segment elevation myocardial infarction.

Leow A, Sia C, Tan B, Chan M, Loh J Clin Cardiol. 2018; 41(10):1297.

PMID: 30225918 PMC: 6490015. DOI: 10.1002/clc.23072.

Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases.

Chen Y, Li G, Liu M Genomics Proteomics Bioinformatics. 2018; 16(1):50-62.

PMID: 29462670 PMC: 6000161. DOI: 10.1016/j.gpb.2017.03.006.

Changes in the pattern of plasma extracellular vesicles after severe trauma.

Kuravi S, Yates C, Foster M, Harrison P, Hazeldine J, Hampson P PLoS One. 2017; 12(8):e0183640.

PMID: 28837705 PMC: 5570308. DOI: 10.1371/journal.pone.0183640.

A Meta-Analysis of Circulating Microvesicles in Patients with Myocardial Infarction.

Wang Z, Cai W, Hu S, Xia Y, Wang Y, Zhang Q Arq Bras Cardiol. 2017; .

PMID: 28700020 PMC: 5576120. DOI: 10.5935/abc.20170102.

References

Morel O, Hugel B, Jesel L, Mallat Z, Lanza F, Douchet M . Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost. 2004; 2(7):1118-26. DOI: 10.1111/j.1538-7836.2004.00805.x. View

Harpaz D, Glikson M, Sidi Y, Hod H . Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. Am Heart J. 1991; 122(5):1492-5. DOI: 10.1016/0002-8703(91)90604-g. View

Hugel B, Socie G, Vu T, Toti F, Gluckman E, Freyssinet J . Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999; 93(10):3451-6. View

Combes V, Simon A, Grau G, Arnoux D, Camoin L, Sabatier F . In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999; 104(1):93-102. PMC: 408397. DOI: 10.1172/JCI4985. View

Triplett D . Antiphospholipid antibodies. Arch Pathol Lab Med. 2002; 126(11):1424-9. DOI: 10.5858/2002-126-1424-AA. View

Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali J . The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest. 1997; 99(7):1546-54. PMC: 507974. DOI: 10.1172/JCI119317. View

Bordron A, Dueymes M, Levy Y, Jamin C, Leroy J, Piette J . The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998; 101(10):2029-35. PMC: 508790. DOI: 10.1172/JCI2261. View

Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N . Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004; 91(4):667-73. DOI: 10.1160/TH03-07-0487. View

Musuraca G, Imperadore F, Terraneo C, De Girolamo P, Cemin C, Bonmassari R . Successful treatment of post-exertion acute myocardial infarction by primary angioplasty and stenting in a patient with antiphospholipid antibody syndrome. Blood Coagul Fibrinolysis. 2004; 15(1):95-8. DOI: 10.1097/00001721-200401000-00015. View

10.

Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y . Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost. 2003; 89(3):506-12. View

11.

Bernal-Mizrachi L, Jy W, Jimenez J, Pastor J, Mauro L, Horstman L . High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003; 145(6):962-70. DOI: 10.1016/S0002-8703(03)00103-0. View

12.

Morel O, Toti F, Hugel B, Freyssinet J . Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol. 2004; 11(3):156-64. DOI: 10.1097/01.moh.0000131441.10020.87. View

13.

Gawaz M, Neumann F, Ott I, Schiessler A, Schomig A . Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996; 93(2):229-37. DOI: 10.1161/01.cir.93.2.229. View

14.

Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S . Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost. 2003; 1(9):2022-30. DOI: 10.1046/j.1538-7836.2003.00349.x. View

15.

Arnout J, Vermylen J . Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003; 1(5):931-42. DOI: 10.1046/j.1538-7836.2003.00125.x. View

16.

Hugel B, Martinez M, Kunzelmann C, Freyssinet J . Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005; 20:22-7. DOI: 10.1152/physiol.00029.2004. View

17.

Morton K, Gavaghan T, Krilis S, Daggard G, Baron D, HICKIE J . Coronary artery bypass graft failure--an autoimmune phenomenon?. Lancet. 1986; 2(8520):1353-7. DOI: 10.1016/s0140-6736(86)92004-0. View

18.

Jy W, Horstman L, Jimenez J, Ahn Y, Biro E, Nieuwland R . Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004; 2(10):1842-51. DOI: 10.1111/j.1538-7836.2004.00936.x. View

19.

Morel O, Jesel L, Hugel B, Douchet M, Zupan M, Chauvin M . Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost. 2003; 1(1):171-7. DOI: 10.1046/j.1538-7836.2003.00010.x. View

20.

Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E . Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003; 17(3):476-8. DOI: 10.1096/fj.02-0574fje. View